Literature DB >> 16002207

Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma.

Michele Gallucci1, Roberta Merola, Antonella Farsetti, Giulia Orlandi, Steno Sentinelli, Piero De Carli, Costantino Leonardo, Paolo Carlini, Fiorella Guadagni, Isabella Sperduti, Anna Maria Cianciulli.   

Abstract

Fluorescence in situ hybridization analysis for evaluation of 7, 8, X chromosomes and EGFR, LPL, MYC, AR genes in 79 neoplastic foci from 56 patients with clinically localized prostate cancer was performed. We found aneusomy for chromosome 7, 8 and X in 74/77 (96.1%), 56/76 (73.7%), 26/70 (37.1%) of examined foci respectively. No specimen was amplified for EGFR and AR genes, only 2/71 (2.8%) specimens showed MYC gene amplified. LPL deletion was present in 52/76 (68.4%) specimens. Statistically association between Gleason score and both chromosome 7 aneusomy and 8p21 deletion was present. The frequency of chromosome 7 aneusomy was statistically higher in T3-4 cases than T2c and T2a-T2b ones. We considered as unfavorable a genetic set if aneusomy for at least two chromosomes and one altered gene were present. The percentage of tumors, with unfavorable genetic pattern, increased from 36.4 to 75.0% in those with Gleason >7 and from 40.0 to 73.7% in those with stage T3 or more. These alterations could be considered potent genetic markers adjunctive to conventional prognostic parameters. Our objective was to establish specific genetic profiles which may discriminate favorable and unfavorable genetic prognosis tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002207     DOI: 10.1016/j.canlet.2005.05.033

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

2.  CSR1 induces cell death through inactivation of CPSF3.

Authors:  Z-H Zhu; Y P Yu; Y-K Shi; J B Nelson; J-H Luo
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

3.  Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.

Authors:  Xiaoyu Qu; Claudio Jeldres; Lena Glaskova; Cynthia Friedman; Sarah Schroeder; Peter S Nelson; Christopher Porter; Min Fang
Journal:  J Mol Diagn       Date:  2016-01-02       Impact factor: 5.568

Review 4.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

5.  Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

Authors:  Suhail K Mithani; Ian M Smith; Joseph A Califano
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

6.  Genetic and epigenetic inactivation of LPL gene in human prostate cancer.

Authors:  Jin Woo Kim; Yu Cheng; Wennuan Liu; Tao Li; Srinivasan Yegnasubramanian; Siqun L Zheng; Jianfeng Xu; William B Isaacs; Bao-Li Chang
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

7.  Lipoprotein lipase as a candidate target for cancer prevention/therapy.

Authors:  Shinji Takasu; Michihiro Mutoh; Mami Takahashi; Hitoshi Nakagama
Journal:  Biochem Res Int       Date:  2011-10-19

8.  A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.

Authors:  Xiaoyu Qu; Grace Randhawa; Cynthia Friedman; Brenda F Kurland; Lena Glaskova; Ilsa Coleman; Elahe Mostaghel; Celestia S Higano; Christopher Porter; Robert Vessella; Peter S Nelson; Min Fang
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.